Novo Nordisk
NVONovo Nordisk makes GLP-1 drugs such as semaglutide, which are used to treat diabetes and weight loss. We follow it because weight-loss drugs are changing what people eat and drink, and Novo Nordisk makes those medicines.
- Ticker
- NVO
- Exchange
- —
- Price
- —
- Change
- —
- As of
- —
- Market cap
- —
- EV/EBIT
- —
- P/E NTM
- —
- FCF yield
- —
- Net debt/EBITDA
- —
- Next earnings
- —
The living report
Bears on our standing view that AI's economy-wide productivity lift does not arrive before 2028. It is proved wrong if productivity jumps much sooner than we expect, or adoption stops spreading.
Members: queues this company for a report on a coming night.
The market record
Free during the preview. Each figure shows only where two independent data providers, Massive and Yahoo, agree on it to the cent; a figure they do not agree on is left out. Dated, not live. It describes; it does not recommend.
close of 9 Nov 2026 · Massive and Yahoo agree
9 Nov 2026 · both providers agree
intraday low 30 Mar 2026 · intraday high 23 Jan 2026 · 251 sessions to 9 Nov 2026 · both providers agree
Filings
Newest first, from EDGAR. Where a piece read a filing, one line of what it said.
Where it sits in the frame
Reports next
Latest disclosed
What it has disclosed
Newest first. Every figure traces to a filing; "Show sources" shows which.
Mentioned in
Every piece that names this company, newest first: what it said, and the standing view it bore on. Written when the piece is committed; never edited, never removed.
Same question
Other companies under Who makes the new weight-loss drugs?
This entry
Prices on this page are dated market records, shown free during the preview, each confirmed by two independent data providers. None is a recommendation.
Record
Written according to the Grant Bishop standard — machine-researched, machine-checked, human-judged; then read and committed by the publisher. Every number traces to a filing or a dated market record; every claim carries a date and what would prove it wrong.
- Verification
- multi-source verified, machine-drafted, human-gated
- As of
- 2026-02-04
- Position disclosure
- The publisher holds index-level U.S. equity exposure and no direct position in any single name discussed.
- Not advice
- General commentary for a general audience. Not advice for your situation.